Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1551


A Case of a Malignant Cutaneous Mixed Tumor (Chondroid Syringoma) of the Scapula Treated With Staged Margin-Controlled Excision.

Lal K, Morrell TJ, Cunningham M, OʼDonnell P, Levin NA, Cornejo KM.

Am J Dermatopathol. 2018 Mar 6. doi: 10.1097/DAD.0000000000001131. [Epub ahead of print]


Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.

Ito Y, Sadar MD.

Res Rep Urol. 2018 Feb 16;10:23-32. doi: 10.2147/RRU.S157116. eCollection 2018. Review.


Differential biological effects of dehydroepiandrosterone (DHEA) between mouse (B16F10) and human melanoma (BLM) cell lines.

Joshi K, Hassan SS, Ramaraj P.

Dermatoendocrinol. 2017 Nov 20;9(1):e1389360. doi: 10.1080/19381980.2017.1389360. eCollection 2017.


Enhanced dissolution of solid dispersions containing bicalutamide subjected to mechanical stress.

Szafraniec J, Antosik A, Knapik-Kowalczuk J, Chmiel K, Kurek M, Gawlak K, Paluch M, Jachowicz R.

Int J Pharm. 2018 Feb 23;542(1-2):18-26. doi: 10.1016/j.ijpharm.2018.02.040. [Epub ahead of print]


TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways.

Liang C, Wang S, Qin C, Bao M, Cheng G, Liu B, Shao P, Lv Q, Song N, Hua L, Gu M, Li J, Wang Z.

Cell Death Dis. 2018 Feb 5;9(2):155. doi: 10.1038/s41419-017-0197-y.


Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms.

Kato T, Komiya A, Yuasa J, Kaga K, Kaga M, Kojima S, Naya Y, Isaka S.

Oncol Lett. 2018 Feb;15(2):2669-2672. doi: 10.3892/ol.2017.7628. Epub 2017 Dec 14.


The Association of A Number of Risk Factors With Depression in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy.

Kim CH, Kim KT, Oh JK, Chung KJ, Kim TB, Jung H, Yoon SJ, Kim KH.

Urol J. 2018 Feb 1. doi: 10.22037/uj.v0i0.4138. [Epub ahead of print]


Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.

Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Sedlmayer F, Wenz F, Zips D, Wiegel T; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO).

Strahlenther Onkol. 2018 Jan 30. doi: 10.1007/s00066-018-1269-3. [Epub ahead of print]


YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth.

Jiang N, Ke B, Hjort-Jensen K, Iglesias-Gato D, Wang Z, Chang P, Zhao Y, Niu X, Wu T, Peng B, Jiang M, Li X, Shang Z, Wang Q, Chang C, Flores-Morales A, Niu Y.

Oncotarget. 2017 Dec 7;8(70):115054-115067. doi: 10.18632/oncotarget.23014. eCollection 2017 Dec 29.


Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.

Koukourakis MI, Kakouratos C, Kalamida D, Mitrakas A, Pouliliou S, Xanthopoulou E, Papadopoulou E, Fasoulaki V, Giatromanolaki A.

Anticancer Drugs. 2018 Apr;29(4):323-333. doi: 10.1097/CAD.0000000000000592.


Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells.

Höti N, Yang S, Hu Y, Shah P, Haffner MC, Zhang H.

Prostate Cancer Prostatic Dis. 2018 Jan 16. doi: 10.1038/s41391-017-0016-7. [Epub ahead of print]


Theca Cell INSL3 and Steroids Together Orchestrate the Growing Bovine Antral Follicle.

Dai Y, Ivell R, Anand-Ivell R.

Front Physiol. 2017 Dec 12;8:1033. doi: 10.3389/fphys.2017.01033. eCollection 2017.


Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017.

Neyman A, Eugster EA.

Pediatr Endocrinol Rev. 2017 Dec;15(2):136-141. doi: 10.17458/per.vol15.2017.nau.treatmentgirlsboys.


Intermittent, low-dose, antiandrogen monotherapy as an alternative therapeutic option for patients with positive surgical margins after radical prostatectomy.

Choi KH, Lee SR, Hong YK, Park DS.

Asian J Androl. 2017 Dec 22. doi: 10.4103/aja.aja_56_17. [Epub ahead of print]


Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.

Ferrari N, Granata I, Capaia M, Piccirillo M, Guarracino MR, Venè R, Brizzolara A, Petretto A, Inglese E, Morini M, Astigiano S, Amaro AA, Boccardo F, Balbi C, Barboro P.

Cell Commun Signal. 2017 Dec 8;15(1):51. doi: 10.1186/s12964-017-0206-x.


Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

Culig Z.

Curr Mol Biol Rep. 2017;3(4):230-235. doi: 10.1007/s40610-017-0079-1. Epub 2017 Oct 23. Review.


Painful testicular metastasis from prostate adenocarcinoma.

Lee KA, Mayer E, Khoo V.

BMJ Case Rep. 2017 Dec 5;2017. pii: bcr-2017-219963. doi: 10.1136/bcr-2017-219963.


Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial.

Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, Motta C, De Leo V, Petraglia F, Lenzi A.

J Clin Endocrinol Metab. 2018 Mar 1;103(3):824-838. doi: 10.1210/jc.2017-01186.


A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.

Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T, Matsuki T, Miura K, Kawakita D, Hirai H, Hoshino E, Kamata S, Saotome T.

Ann Oncol. 2017 Dec 1. doi: 10.1093/annonc/mdx771. [Epub ahead of print]


Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.

Fiandalo MV, Wilton JH, Mantione KM, Wrzosek C, Attwood KM, Wu Y, Mohler JL.

Prostate. 2018 Feb;78(3):213-221. doi: 10.1002/pros.23459. Epub 2017 Dec 1.


Supplemental Content

Loading ...
Support Center